Taking a risk: A therapeutic focus on ataxin-2 in amyotrophic lateral sclerosis?

Trends in Molecular Medicine

Volumn 20, Issue 1, 2014, Pages 25-35

  Van den Heuvel, Dianne M A ^a   Harschnitz, Oliver ^a   van den Berg, Leonard H ^a   Pasterkamp, R Jeroen ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Amyotrophic lateral sclerosis; Antisense oligonucleotide therapy; Ataxin 2; FUS; Neurodegeneration; TDP 43

Indexed keywords

ATAXIN 2; PEPTIDES AND PROTEINS; POLYGLUTAMINE; RNA; TAR DNA BINDING PROTEIN; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; CALCIUM SIGNALING; ENDOCYTOSIS; ENDOPLASMIC RETICULUM; GENE FUNCTION; GENE TARGETING; GENETIC RISK; GENETIC SUSCEPTIBILITY; GOLGI COMPLEX; HUMAN; MOTONEURON; MUSCLE WEAKNESS; NEUROPATHOLOGY; NONHUMAN; PROTEIN AGGREGATION; RESPIRATORY FAILURE; REVIEW; RNA METABOLISM; RNA PROCESSING; TDP 43 PROTEINOPATHY;

AMYOTROPHIC LATERAL SCLEROSIS; ANTISENSE OLIGONUCLEOTIDE THERAPY; ATAXIN-2; FUS; NEURODEGENERATION; TDP-43;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DNA-BINDING PROTEINS; HUMANS; MOTOR NEURONS; NERVE TISSUE PROTEINS; PEPTIDES; PROTEIN BINDING; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RISK FACTORS; RNA; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 84891371641     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2013.09.001     Document Type: Review

References (116)

1. Alonso A. Incidence and lifetime risk of motor neuron disease in the United Kingdom: a population-based study. Eur. J. Neurol. 2009, 16:745-751.
2. Chio A., et al. Epidemiology of ALS in Italy: a 10-year prospective population-based study. Neurology 2009, 72:725-731.
3. Miller R.G., et al. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst. Rev. 2007, 1:CD001447.
4. Byrne S., et al. Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysis. J. Neurol. Neurosurg. Psychiatry 2011, 82:623-627.
5. Rosen D.R., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993, 362:59-62.
6. Lattante S., et al. TARDBP and FUS mutations associated with amyotrophic lateral sclerosis: summary and update. Hum. Mutat. 2013, 34:812-826.
7. Dejesus-Hernandez M., et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011, 72:245-256.
8. Renton A.E., et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011, 72:257-268.
9. Blauw H.M., et al. NIPA1 polyalanine repeat expansions are associated with amyotrophic lateral sclerosis. Hum. Mol. Genet. 2012, 21:2497-2502.
10. Diekstra F.P., et al. UNC13A is a modifier of survival in amyotrophic lateral sclerosis. Neurobiol. Aging 2012, 33:630-638.
11. Elden A.C., et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 2010, 466:1069-1075.
12. Farg M.A., et al. Ataxin-2 interacts with FUS and intermediate-length polyglutamine expansions enhance FUS-related pathology in amyotrophic lateral sclerosis. Hum. Mol. Genet. 2013, 22:717-728.
13. Hart M.P., Gitler A.D. ALS-associated ataxin 2 polyQ expansions enhance stress-induced caspase 3 activation and increase TDP-43 pathological modifications. J. Neurosci. 2012, 32:9133-9142.
14. Nihei Y., et al. Roles of ataxin-2 in pathological cascades mediated by TAR DNA-binding protein 43 (TDP-43) and Fused in Sarcoma (FUS). J. Biol. Chem. 2012, 287:41310-41323.
15. Ross O.A., et al. Ataxin-2 repeat-length variation and neurodegeneration. Hum. Mol. Genet. 2011, 20:3207-3212.
16. Sequeiros J., et al. Consensus and controversies in best practices for molecular genetic testing of spinocerebellar ataxias. Eur. J. Hum. Genet. 2010, 18:1188-1195.
17. Imbert G., et al. Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat. Genet. 1996, 14:285-291.
18. Gispert S., et al. Chromosomal assignment of the second locus for autosomal dominant cerebellar ataxia (SCA2) to chromosome 12q23-24.1. Nat. Genet. 1993, 4:295-299.
19. Pulst S.M., et al. Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nat. Genet. 1996, 14:269-276.
20. Sanpei K., et al. Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT. Nat. Genet. 1996, 14:277-284.
21. Costanzi-Porrini S., et al. An interrupted 34-CAG repeat SCA-2 allele in patients with sporadic spinocerebellar ataxia. Neurology 2000, 54:491-493.
22. Fernandez M., et al. Late-onset SCA2: 33 CAG repeats are sufficient to cause disease. Neurology 2000, 55:569-572.
23. Lee T., et al. Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients. Hum. Mol. Genet. 2011, 20:1697-1700.
24. Van Damme P., et al. Expanded ATXN2 CAG repeat size in ALS identifies genetic overlap between ALS and SCA2. Neurology 2011, 76:2066-2072.
25. Lee T., et al. Evaluating the prevalence of polyglutamine repeat expansions in amyotrophic lateral sclerosis. Neurology 2011, 76:2062-2065.
26. Ramos E.M., et al. Prevalence of Huntington's disease gene CAG repeat alleles in sporadic amyotrophic lateral sclerosis patients. Amyotroph. Lateral Scler. 2012, 13:265-269.
27. Gispert S., et al. The modulation of amyotrophic lateral sclerosis risk by ataxin-2 intermediate polyglutamine expansions is a specific effect. Neurobiol. Dis. 2012, 45:356-361.
28. Conforti F.L., et al. Ataxin-1 and ataxin-2 intermediate-length PolyQ expansions in amyotrophic lateral sclerosis. Neurology 2012, 79:2315-2320.
29. Williams D.R., Lees A.J. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol. 2009, 8:270-279.
30. Nielsen T.T., et al. ATXN2 with intermediate-length CAG/CAA repeats does not seem to be a risk factor in hereditary spastic paraplegia. J. Neurol. Sci. 2012, 321:100-102.
31. Lu C.S., et al. The parkinsonian phenotype of spinocerebellar ataxia type 2. Arch. Neurol. 2004, 61:35-38.
32. Shan D.E., et al. Spinocerebellar ataxia type 2 presenting as familial levodopa-responsive parkinsonism. Ann. Neurol. 2001, 50:812-815.
33. Blokhuis A.M., et al. Protein aggregation in amyotrophic lateral sclerosis. Acta Neuropathol. 2013, 125:777-794.
34. Neumann M., et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006, 314:130-133.
35. Mackenzie I.R., et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann. Neurol. 2007, 61:427-434.
36. Tan C.F., et al. TDP-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosis with or without SOD1 gene mutation. Acta Neuropathol. 2007, 113:535-542.
37. Barmada S.J., et al. Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. J. Neurosci. 2010, 30:639-649.
38. Wiedemeyer R., et al. Ataxin-2 promotes apoptosis of human neuroblastoma cells. Oncogene 2003, 22:401-411.
39. Hart M.P., et al. Distinct TDP-43 pathology in ALS patients with ataxin 2 intermediate-length polyQ expansions. Acta Neuropathol. 2012, 124:221-230.
40. Huynh D.P., et al. Expression of ataxin-2 in brains from normal individuals and patients with Alzheimer's disease and spinocerebellar ataxia 2. Ann. Neurol. 1999, 45:232-241.
41. Mangus D.A., et al. Pbp1p, a factor interacting with Saccharomyces cerevisiae poly(A)-binding protein, regulates polyadenylation. Mol. Cell. Biol. 1998, 18:7383-7396.
42. Satterfield T.F., Pallanck L.J. Ataxin-2 and its Drosophila homolog, ATX2, physically assemble with polyribosomes. Hum. Mol. Genet. 2006, 15:2523-2532.
43. Mangus D.A., et al. Positive and negative regulation of poly(A) nuclease. Mol. Cell. Biol. 2004, 24:5521-5533.
44. Lim C., Allada R. ATAXIN-2 activates PERIOD translation to sustain circadian rhythms in Drosophila. Science 2013, 340:875-879.
45. Zhang Y., et al. A role for Drosophila ATX2 in activation of PER translation and circadian behavior. Science 2013, 340:879-882.
46. McCann C., et al. The Ataxin-2 protein is required for microRNA function and synapse-specific long-term olfactory habituation. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:E655-E662.
47. Nonhoff U., et al. Ataxin-2 interacts with the DEAD/H-box RNA helicase DDX6 and interferes with P-bodies and stress granules. Mol. Biol. Cell 2007, 18:1385-1396.
48. Ralser M., et al. An integrative approach to gain insights into the cellular function of human ataxin-2. J. Mol. Biol. 2005, 346:203-214.
49. Kaehler C., et al. Ataxin-2-like is a regulator of stress granules and processing bodies. PLoS ONE 2012, 7:e50134.
50. Shibata H., et al. A novel protein with RNA-binding motifs interacts with ataxin-2. Hum. Mol. Genet. 2000, 9:1303-1313.
51. Drost J., et al. Ataxin-2 modulates the levels of Grb2 and Src but not Ras signaling. J. Mol. Neurosci. 2013, 51:68-81.
52. Nonis D., et al. Ataxin-2 associates with the endocytosis complex and affects EGF receptor trafficking. Cell. Signal. 2008, 20:1725-1739.
53. Kiehl T.R., et al. The ortholog of human ataxin-2 is essential for early embryonic patterning in C. elegans. J. Mol. Neurosci. 2000, 15:231-241.
54. Satterfield T.F., et al. A Drosophila homolog of the polyglutamine disease gene SCA2 is a dosage-sensitive regulator of actin filament formation. Genetics 2002, 162:1687-1702.
55. Kiehl T.R., et al. Generation and characterization of Sca2 (ataxin-2) knockout mice. Biochem. Biophys. Res. Commun. 2006, 339:17-24.
56. Lastres-Becker I., et al. Insulin receptor and lipid metabolism pathology in ataxin-2 knock-out mice. Hum. Mol. Genet. 2008, 17:1465-1481.
57. Huynh D.P., et al. Dissociated fear and spatial learning in mice with deficiency of ataxin-2. PLoS ONE 2009, 4:e6235.
58. Song C., et al. Expression of full-length polyglutamine-expanded Huntingtin disrupts growth factor receptor signaling in rat pheochromocytoma (PC12) cells. J. Biol. Chem. 2002, 277:6703-6707.
59. Chen X., et al. Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 3. J. Neurosci. 2008, 28:12713-12724.
60. Liu J., et al. Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 2. J. Neurosci. 2009, 29:9148-9162.
61. Tang T.S., et al. Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. Neuron 2003, 39:227-239.
62. Bertoni A., et al. Early and late events induced by polyQ-expanded proteins: identification of a common pathogenic property of polYQ-expanded proteins. J. Biol. Chem. 2011, 286:4727-4741.
63. Tassone F., et al. FMR1 RNA within the intranuclear inclusions of fragile X-associated tremor/ataxia syndrome (FXTAS). RNA Biol. 2004, 1:103-105.
64. Li L.B., Bonini N.M. Roles of trinucleotide-repeat RNA in neurological disease and degeneration. Trends Neurosci. 2010, 33:292-298.
65. Ash P.E., et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron 2013, 77:639-646.
66. Mori K., et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science 2013, 339:1335-1338.
67. Moseley M.L., et al. Bidirectional expression of CUG and CAG expansion transcripts and intranuclear polyglutamine inclusions in spinocerebellar ataxia type 8. Nat. Genet. 2006, 38:758-769.
68. Pearson C.E. Repeat associated non-ATG translation initiation: one DNA, two transcripts, seven reading frames, potentially nine toxic entities! PLoS Genet. 2011, 7:e1002018.
69. Cho D.H., et al. Antisense transcription and heterochromatin at the DM1 CTG repeats are constrained by CTCF. Mol. Cell 2005, 20:483-489.
70. Yu Z., et al. Triplet repeat-derived siRNAs enhance RNA-mediated toxicity in a Drosophila model for myotonic dystrophy. PLoS Genet. 2011, 7:e1001340.
71. Southwell A.L., et al. Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases. Trends Mol. Med. 2012, 18:634-643.
72. Evers M.M., et al. Targeting several CAG expansion diseases by a single antisense oligonucleotide. PLoS ONE 2011, 6:e24308.
73. Hu J., et al. Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. Nat. Biotechnol. 2009, 27:478-484.
74. Kordasiewicz H.B., et al. Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron 2012, 74:1031-1044.
75. Banks W.A., et al. Delivery across the blood-brain barrier of antisense directed against amyloid β: reversal of learning and memory deficits in mice overexpressing amyloid precursor protein. J. Pharmacol. Exp. Ther. 2001, 297:1113-1121.
76. Alter J., et al. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat. Med. 2006, 12:175-177.
77. Passini M.A., et al. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci. Transl. Med. 2011, 3:72ra18.
78. Williams J.H., et al. Oligonucleotide-mediated survival of motor neuron protein expression in CNS improves phenotype in a mouse model of spinal muscular atrophy. J. Neurosci. 2009, 29:7633-7638.
79. Smith R.A., et al. Antisense oligonucleotide therapy for neurodegenerative disease. J. Clin. Invest. 2006, 116:2290-2296.
80. Miller T.M., et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 2013, 12:435-442.
81. Beerli R.R., et al. Toward controlling gene expression at will: specific regulation of the erbB-2/HER-2 promoter by using polydactyl zinc finger proteins constructed from modular building blocks. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:14628-14633.
82. Beerli R.R., et al. Positive and negative regulation of endogenous genes by designed transcription factors. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:1495-1500.
83. Bogdanove A.J., Voytas D.F. TAL effectors: customizable proteins for DNA targeting. Science 2011, 333:1843-1846.
84. Christian M., et al. Targeting DNA double-strand breaks with TAL effector nucleases. Genetics 2010, 186:757-761.
85. Li T., et al. Modularly assembled designer TAL effector nucleases for targeted gene knockout and gene replacement in eukaryotes. Nucleic Acids Res. 2011, 39:6315-6325.
86. Gaj T., et al. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 2013, 31:397-405.
87. Takahashi K., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
88. Ousterout D.G., et al. Reading frame correction by targeted genome editing restores dystrophin expression in cells from Duchenne muscular dystrophy patients. Mol. Ther. 2013, 21:1718-1726.
89. Soldner F., et al. Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell 2011, 146:318-331.
90. Bauer P.O., et al. Can ataxin-2 be down-regulated by allele-specific de novo DNA methylation in SCA2 patients?. Med. Hypotheses 2004, 63:1018-1023.
91. Xu G.L., Bestor T.H. Cytosine methylation targetted to pre-determined sequences. Nat. Genet. 1997, 17:376-378.
92. Yang Y.M., et al. A small molecule screen in stem-cell-derived motor neurons identifies a kinase inhibitor as a candidate therapeutic for ALS. Cell Stem Cell 2013, 12:713-726.
93. Kwiatkowski T.J., et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009, 323:1205-1208.
94. Vance C., et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009, 323:1208-1211.
95. Rutherford N.J., et al. Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet. 2008, 4:e1000193.
96. Sreedharan J., et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008, 319:1668-1672.
97. Pasinelli P., Brown R.H. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat. Rev. Neurosci. 2006, 7:710-723.
98. Lagier-Tourenne C., et al. TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. Hum. Mol. Genet. 2010, 19:R46-R64.
99. Johnson B.S., et al. TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J. Biol. Chem. 2009, 284:20329-20339.
100. Dormann D., et al. ALS-associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import. EMBO J. 2010, 29:2841-2857.
101. Levine T.P., et al. The product of C9orf72, a gene strongly implicated in neurodegeneration, is structurally related to DENN Rab-GEFs. Bioinformatics 2013, 29:499-503.
102. Greenway M.J., et al. ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis. Nat. Genet. 2006, 38:411-413.
103. Chen Y.Z., et al. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am. J. Hum. Genet. 2004, 74:1128-1135.
104. Deng H.X., et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 2011, 477:211-215.
105. Nishimura A.L., et al. A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am. J. Hum. Genet. 2004, 75:822-831.
106. Parkinson N., et al. ALS phenotypes with mutations in CHMP2B (charged multivesicular body protein 2B). Neurology 2006, 67:1074-1077.
107. van Es M.A., et al. Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat. Genet. 2009, 41:1083-1087.
108. Gros-Louis F., et al. A frameshift deletion in peripherin gene associated with amyotrophic lateral sclerosis. J. Biol. Chem. 2004, 279:45951-45956.
109. Corcia P., et al. The importance of the SMN genes in the genetics of sporadic ALS. Amyotroph. Lateral Scler. 2009, 10:436-440.
110. Estrada R., et al. Spinocerebellar ataxia 2 (SCA2): morphometric analyses in 11 autopsies. Acta Neuropathol. 1999, 97:306-310.
111. Kasumu A.W., et al. Selective positive modulator of calcium-activated potassium channels exerts beneficial effects in a mouse model of spinocerebellar ataxia type 2. Chem. Biol. 2012, 19:1340-1353.
112. Huynh D.P., et al. Nuclear localization or inclusion body formation of ataxin-2 are not necessary for SCA2 pathogenesis in mouse or human. Nat. Genet. 2000, 26:44-50.
113. Koyano S., et al. Neuronal intranuclear inclusions in spinocerebellar ataxia type 2: triple-labeling immunofluorescent study. Neurosci. Lett. 1999, 273:117-120.
114. Pang J.T., et al. Neuronal intranuclear inclusions in SCA2: a genetic, morphological and immunohistochemical study of two cases. Brain 2002, 125:656-663.
115. Mori F., et al. FUS co-localizes with polyglutamine, but not with TDP-43 in neuronal intranuclear inclusions in spinocerebellar ataxia type 2. Neuropathol. Appl. Neurobiol. 2013, 10.1111/nan.12075.
116. Toyoshima Y., Takahashi H. TDP-43 pathology in polyglutamine diseases: with reference to amyotrophic lateral sclerosis. Neuropathology 2013, 10.1111/neup.12053.